275 related articles for article (PubMed ID: 26606782)
21. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
22. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
[TBL] [Abstract][Full Text] [Related]
24. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
25. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
27. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
28. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
[TBL] [Abstract][Full Text] [Related]
29. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
[TBL] [Abstract][Full Text] [Related]
30. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
31. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
32. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Li M; Liu CL; Wang XY; Xue XM; Gao ZF
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
[TBL] [Abstract][Full Text] [Related]
34. Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy.
Hassan U; Mushtaq S; Mamoon N; Asghar AH; Ishtiaq S
Asian Pac J Cancer Prev; 2012; 13(4):1341-7. PubMed ID: 22799329
[TBL] [Abstract][Full Text] [Related]
35. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C
J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841
[TBL] [Abstract][Full Text] [Related]
36. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
37. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma.
Tagawa H; Suguro M; Tsuzuki S; Matsuo K; Karnan S; Ohshima K; Okamoto M; Morishima Y; Nakamura S; Seto M
Blood; 2005 Sep; 106(5):1770-7. PubMed ID: 15886317
[TBL] [Abstract][Full Text] [Related]
38. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Delabie J; Ott G; Müller-Hermelink HK; Campo E; Braziel RM; Jaffe ES; Pan Z; Farinha P; Smith LM; Falini B; Banham AH; Rosenwald A; Staudt LM; Connors JM; Armitage JO; Chan WC
Blood; 2004 Jan; 103(1):275-82. PubMed ID: 14504078
[TBL] [Abstract][Full Text] [Related]
39. [Significance of CD138 in immunohistochemical profiles and its correlation with prognosis in diffuse large B-cell lymphoma].
Zhang HW; Chen ZW; Wang JF; Cheng NL
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):115-20. PubMed ID: 21575479
[TBL] [Abstract][Full Text] [Related]
40. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
